nach oben

Erschienen in:

2013 | OriginalPaper | Buchkapitel

5. Ersttrimesterscreening

verfasst von : Karl-Oliver Kagan, Prof. Dr. med., Harald Abele, PD Dr., Markus Hoopmann, PD Dr. med.

Erschienen in: Ultraschalldiagnostik in Geburtshilfe und Gynäkologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ein Screeningtest muss grundsätzlich von einem diagnostischen Test unterschieden werden. Mithilfe eines diagnostischen Tests, wie zum Beispiel der Amniozentese oder der Chorionzottenbiopsie, wird eine fetale Chromosomenstörung, wie die Trisomie 21, 18 oder 13 in aller Regel eindeutig erkannt. Diese Tests tragen aber ein Fehlgeburtsrisiko von etwa 0,5 % und sind kostenintensiv (Tabor u. Alfirevic 2010). Demgegenüber stehen Screeningtests, wie das Ersttrimesterscreening, die einerseits nicht mit einem Fehlgeburtsrisiko vergesellschaftet und andererseits kostengünstiger sind. Durch sie wird aber nur das Risiko für das Vorliegen einer entsprechenden Erkrankung ermittelt.

Abele H, Wagner N, Hoopmann M, Grischke EM, Wallwiener D, Kagan KO (2010) Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol 35(5):525–529CrossRefPubMed

Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31(1):66–74CrossRefPubMed

Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH (2013) Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 41(1):26–32CrossRefPubMed

Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH (2005) Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 26(2):154–157CrossRefPubMed

Benn P, Cuckle H, Pergament E (2013) Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 42(1):15–33CrossRefPubMed

Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11–13 weeks. Prenat Diagn 31(1):75–83CrossRefPubMed

Bilardo CM, Muller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK (2007) Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 30(1):11–18CrossRefPubMed

Bilardo CM, Timmerman E, Pajkrt E, van Maarle M (2010) Increased nuchal translucency in euploid fetuses – what should we be telling the parents? Prenat Diagn 30(2):93–102CrossRefPubMed

Borenstein M, Persico N, Kagan KO, Gazzoni A, Nicolaides KH (2008) Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 32(1):5–11CrossRefPubMed

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116(2 Pt 1):402–414CrossRefPubMed

Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH (2006) Nasal bone in first–trimester screening for trisomy 21. Am J Obstet Gynecol 195(1):109–114CrossRefPubMed

Cicero S, Dezerega V, Andrade E, Scheier M, Nicolaides KH (2003) Learning curve for sonographic examination of the fetal nasal bone at 11–14 weeks. Ultrasound Obstet Gynecol 22(2):135–137CrossRefPubMed

Cuckle H, Benn P, Wright D (2005) Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 29(4):252–257CrossRefPubMed

Cuckle HS (2011) Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 32(Suppl):S42–S48CrossRefPubMed

Cuckle HS, Wald NJ, Thompson SG (1987) Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94(5):387–402CrossRefPubMed

Dan S, Wang W, Ren J, Xu Z, Hu H, Li Y et al (2012) Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 32(13):1225–1232CrossRefPubMed

De Souza E, Halliday J, Chan A, Bower C, Morris JK (2009) Recurrence risks for trisomies 13, 18 and 21. Am J Med Genet A 149(12):2716–2722CrossRef

Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337:a2547CrossRefPubMedPubMedCentral

Fan HC, Gu W, Wang J, Blumenfeld YJ, El-Sayed YY, Quake SR (2012) Non-invasive prenatal measurement of the fetal genome. Nature 487(7407):320–324CrossRefPubMedPubMedCentral

Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH (2011) Maternal serum visfatin at 11–13 weeks of gestation in gestational diabetes mellitus. Clin Chem 57(4):609–613CrossRefPubMed

Flenady V, Koopmans L, Middleton P, Frøen JF, Smith GC, Gibbons K, Coory M, Gordon A, Ellwood D, McIntyre HD, Fretts R, Ezzati M (2011) Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet 377(9774):1331–1340CrossRefPubMed

Fuchs IB, Muller H, Abdul-Khaliq H, Harder T, Dudenhausen JW, Henrich W (2007) Immediate and long-term outcomes in children with prenatal diagnosis of selected isolated congenital heart defects. Ultrasound Obstet Gynecol 29(1):38–43CrossRefPubMed

Greco E, Lange A, Ushakov F, Calvo JR, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks. Prenat Diagn 31(1):84–89CrossRefPubMed

Hoopmann M, Abele H, Wagner N, Wallwiener D, Kagan KO (2010) Performance of 36 Different Weight Estimation Formulae in Fetuses with Macrosomia. Fetal Diagn Ther 27(4):204–213CrossRefPubMed

Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study. BMJ 318(7176):81–85CrossRefPubMedPubMedCentral

Kagan K, Hoopmann M, Kozlowski P (2012) Assessment of Foetal DNA in Maternal Blood – A Useful Tool in the Hands of Prenatal Specialists. Geburtsh Frauenheilk 72(11):998–1003CrossRefPubMedPubMedCentral

Kagan KO, Eiben B, Kozlowski P (2013) Kombiniertes Ersttrimesterscreening und zell-freie fetale DNA – „Next generation screening“. Ultraschall in Med (in press)

Kagan KO, Anderson JM, Anwandter G, Neksasova K, Nicolaides KH (2008) Screening for triploidy by the risk algorithms for trisomies 21 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation. Prenat Diagn 28(13):1209–1213CrossRefPubMed

Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH (2006) Relation between increased fetal nuchal translucency, thickness and chromosomal defects. Obstet Gynecol 107(1):6–10CrossRefPubMed

Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH (2009) Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33(3):259–264CrossRefPubMed

Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34(1):14–18CrossRefPubMed

Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH (2007) Discordance in nuchal translucency, thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 29(5):527–532CrossRefPubMed

Kagan KO, Staboulidou I, Cruz J, Wright D, Nicolaides KH (2010) Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing. Ultrasound Obstet Gynecol 36(5):542–547CrossRefPubMed

Kagan KO, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH (2010) The 11–13-week scan: diagnosis and outcome of holoprosencephaly exomphalos and megacystis. Ultrasound Obstet Gynecol 36(1):10–14CrossRefPubMed

Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH (2009) Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 33(1):18–22CrossRefPubMed

Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH (2008) Screening for trisomy 21 by maternal age fetal nuchal translucency thickness free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 31(6):618–624CrossRefPubMed

Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH (2009) Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 33(6):657–664CrossRefPubMed

Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31(5):493–502CrossRefPubMed

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH (2008) Screening for trisomies 21 18 and 13 by maternal age fetal nuchal translucency fetal heart rate free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod 23(9):1968–1975CrossRefPubMed

Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH (2011) Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 29(2):148–154CrossRefPubMed

Kitzman JO, Snyder MW, Ventura M, Lewis AP, Qiu R, Simmons LE et al (2012) Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med 4(137):137ra76CrossRefPubMedPubMedCentral

Kuc S, Wortelboer EJ, Koster MP, de Valk HW, Schielen PC, Visser GH (2011) Prediction of macrosomia at birth in type-1 and 2 diabetic pregnancies with biomarkers of early placentation. BJOG 118(6):748–754CrossRefPubMed

Liang D, Lv W, Wang H, Xu L, Liu J, Li H et al (2013) Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn 33(5):409–415CrossRefPubMed

Lo YM, Corbetta N, Chamberlain PF, Redman CW, Sargent IL, Rai V et al (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350(9076):485–487CrossRefPubMed

Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K (2011) A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 37(1):38–47CrossRefPubMed

Maiz N, Kagan KO, Milovanovic Z, Celik E, Nicolaides KH (2008) Learning curve for Doppler assessment of ductus venosus flow at 11 + 0 to 13 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 31(5):503–506CrossRefPubMed

Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH (2009) Ductus venosus Doppler in screening for trisomies 21,18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33(5):512–517CrossRefPubMed

Malone FD (2005) Nuchal translucency-based Down syndrome screening: barriers to implementation. Semin Perinatol 29(4):272–276CrossRefPubMed

Matias A, Montenegro N, Loureiro T, Cunha M, Duarte S, Freitas D, Severo M (2010) Screening for twin–twin transfusion syndrome at 11–14 weeks of pregnancy: the key role of ductus venosus blood flow assessment. Ultrasound Obstet Gynecol 35(2):142–148CrossRefPubMed

Mazloom AR, Džakula Z, Oeth P, Tynan J, Jensen T, Wang H et al (2013) Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn 33(6):591–597CrossRefPubMed

Merz E, Thode C, Alkier A, Eiben B, Hackelöer BJ, Hansmann M, Huesgen G, Kozlowski P, Pruggmaier M, Wellek S (2008) A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in der Medizin 29(6):639–645CrossRefPubMed

Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH (2006) Cystic hygromas nuchal edema and nuchal translucency at 11–14 weeks of gestation. Obstet Gynecol 107(3):678–683CrossRefPubMed

Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH (2011) Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 31(2):135–141CrossRefPubMed

Nicolaides KH (2003) Screening for chromosomal defects. Ultrasound Obstet Gynecol 21(4):313–321CrossRefPubMed

Nicolaides KH (2011) A model for a new pyramid of prenatal care based on the 11 to 13 weeks’ assessment. Prenat Diagn 31(1):3–6CrossRefPubMed

Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25(3):221–226CrossRefPubMed

Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G (2012) Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 207(5):374.e1–374.e6CrossRef

Papatheodorou S, Evangelou E, Makrydimas G, Ioannidis J (2011) First-trimester ductus venosus screening for cardiac defects: a meta-analysis. BJOG: an international journal of obstetrics and gynaecology Jun 14

Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH (2011) Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstetrics and gynecology 117(6):1384–1391CrossRefPubMed

Persico N, Moratalla J, Lombardi CM, Zidere V, Allan L, Nicolaides KH (2011) Fetal echocardiography at 11–13 weeks by transabdominal high-frequency ultrasound. Ultrasound Obstet Gynecol 37(3):296–301CrossRefPubMed

Plasencia W, Garcia R, Pereira S, Akolekar R, Nicolaides KH (2011) Criteria for Screening and Diagnosis of Gestational Diabetes Mellitus in the First Trimester of Pregnancy. Fetal Diagn Ther Apr 1CrossRefPubMed

Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH (2011) Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates. Prenat Diagn 31(1):58–65CrossRefPubMed

Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH (2011) First-trimester prediction of macrosomia. Fetal Diagn Ther 29(2):139–147CrossRefPubMed

Poon LC, v Kametas NA, Pandeva I, Valencia C, Nicolaides KH (2008) Mean arterial pressure at 11 (+0) to 13 (+6) weeks in the prediction of preeclampsia. Hypertension 51(4):1027–1033CrossRefPubMed

Scazzocchio E, Figueras F (2011) Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 23(2):65–71CrossRefPubMed

Schulte-Vallentin M, Schindler H (1992) Non-echogenic nuchal oedema as a marker in trisomy 21 screening. Lancet 25(339):8800

Senat MV, Frydman R (2007) Increased nuchal translucency with normal karyotype. Gynecol Obstet Fertil 35(6):507–515CrossRefPubMed

Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125):343–346CrossRefPubMed

Snijders RJ, Sebire NJ, Nicolaides KH (1995) Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 10(6):356–367CrossRefPubMed

Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH (2005) Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192(4):1005–1021CrossRefPubMed

Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH (2003) Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22(2):142–148CrossRefPubMed

Spencer K, Cowans NJ, Avgidou K, Nicolaides KH (2006) First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 28(5):637–643CrossRefPubMed

Spencer K, Kagan KO, Nicolaides KH (2008) Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 28(1):49–52CrossRefPubMed

Spencer K, Nicolaides KH (2003) Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 110(3):276–280CrossRefPubMed

Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH (2011) Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 31(1):90–102CrossRefPubMed

Szabo J, Gellen J (1990) Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester Lancet Nov 3: 336 (8723): 1133

Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 27(1):1–7CrossRefPubMed

Tabor A, Vestergaard CH, Lidegaard O (2009) Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 34(1):19–24CrossRefPubMed

Tegnander E, Williams W, Johansen OJ, Blaas HG, Eik-Nes SH (2006) Prenatal detection of heart defects in a non-selected population of 30,149 fetuses – detection rates and outcome. Ultrasound Obstet Gynecol 27(3):252–265CrossRefPubMed

The Fetal Medicine Foundation. www. fetalmedicine. com, aufgerufen am 212012

To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH (2006) Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 27(4):362–367CrossRefPubMed

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM (2003) First and second trimester antenatal screening for Down’s syndrome: the results of the Serum Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10(2):56–104PubMed

Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH (2008) A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31(4):376–383CrossRefPubMed

Wright D, Spencer K, Kagan KK, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH (2010) First-trimester combined screening for trisomy 21 at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 36(4):404–411CrossRefPubMed

Wright D, Syngelaki A, Staboulidou I, Cruz Jde J, Nicolaides KH (2011) Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenat Diagn 31(1):16–21CrossRefPubMed

Titel: Ersttrimesterscreening
verfasst von: Karl-Oliver Kagan, Prof. Dr. med.
Harald Abele, PD Dr.
Markus Hoopmann, PD Dr. med.
Verlag: Springer Berlin Heidelberg
Buch: Ultraschalldiagnostik in Geburtshilfe und Gynäkologie
Print ISBN: 978-3-642-29632-1

Electronic ISBN: 978-3-642-29633-8

Copyright-Jahr: 2013
DOI: https://doi.org/10.1007/978-3-642-29633-8_5

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

5. Ersttrimesterscreening

Zusammenfassung

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie